Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
+$0.09 today
- Market cap
- $595.91M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
Volume 0.88M
Average 1.07M
IMMX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Immix Biopharma, Inc.NASDAQ: IMMX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $4.82M rose 78.1% year over year, ahead of the +34.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 6.6% from the prior quarter. Over 3 fiscal years it compounded at +50.4% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +20.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.82M-6.6% QoQ
- Last fiscal yearDec 2025
- $13.7M+20.3% YoY
- LTMMar 2026
- $15.81M+34.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +78.1% | -100.0% | -178.1 pp |
| 1 year | +20.3% | -100.0% | -120.3 pp |
| 3-year CAGR | +50.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 13.7M USD
- Year-over-year change
- +20.3%
- 4-year CAGR
- +82.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.7M | +20.3% |
| FY2024 | 2024-12-31 | 11.38M | +53.7% |
| FY2023 | 2023-12-31 | 7.41M | +84.1% |
| FY2022 | 2022-12-31 | 4.02M | +228.3% |
| FY2021 | 2021-12-31 | 1.23M | — |
Selling, General & Admin vs competitors
How IMMX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +34.6% is the 4th highest of 11, against a peer median of +24.4%.
- Over three fiscal years its annual growth of +50.4% compares with a peer median of +4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $106M USD | -7.8% | +1.9% | 90.6% | |
| LTM Aug 2026 | $78.21M USD | +57.0% | +11.6% | 11.1% | |
| FY2025 | €72.87M EUR | +87.3% | +113.4% | — | |
| LTM Sep 2026 | $51.3M USD | +21.7% | +17.2% | 45802.7% | |
| LTM Mar 2026 | $38.15M USD | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $31.1M USD | -1.0% | -11.4% | 87.5% | |
| LTM Mar 2026 | $23.53M USD | +30.1% | +11.7% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥21.46M CNY | +128.2% | -71.8% | — |
| LTM Mar 2026 | $15.81M USD | +34.6% | +50.4% | — | |
| LTM Mar 2026 | $13.02M USD | +27.1% | +2.6% | 2479.6% | |
| FY2025 | A$8.64M AUD | -2.4% | +6.2% | 171.4% | |
| Peer median (excluding IMMX) | — | +24.4% | +4.4% | 90.6% | |
Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 364.5K |
| Gross Profit | 0 | 0 | 0 | 0 | (364.5K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 126.53K | 4.2M | 8.74M | 11.29M | 16.26M |
| Selling, General & Admin | 1.23M | 4.02M | 7.41M | 11.38M | 13.7M |
| Operating Expenses | 1.35M | 8.22M | 16.14M | 22.67M | 26.85M |
| Depreciation & Amortization | 2.47K | 2.14K | 5.47K | 115.39K | 364.5K |
| EBITDA | (24.2M) | (8.22M) | (15.56M) | (21.54M) | (29.04M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.35M) | (8.22M) | (16.14M) | (22.67M) | (27.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 572.01K | 1.02M | 555.53K |
| Interest Expense | 179.85K | 497 | 0 | 0 | 0 |
| Other Income / Expenses | (23.03M) | (497) | 572.01K | 1.02M | (2.19M) |
| Income Before Tax | (24.38M) | (8.22M) | (15.57M) | (21.66M) | (29.4M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 6.01K | 10.27K | 26.42K | 41.04K | 37.72K |
| Net Income | (24.38M) | (8.23M) | (15.43M) | (21.61M) | (29.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (6.64) | (0.59) | (0.89) | (0.76) | (0.89) |
| EPS (Diluted) | (6.64) | (0.59) | (0.89) | (0.76) | (0.89) |
| Weighted Avg Shares | 3.67M | 13.89M | 17.34M | 28.29M | 32.97M |
| Weighted Avg Shares (Diluted) | 3.67M | 13.89M | 17.34M | 28.29M | 32.97M |
Immix Biopharma, Inc.
NASDAQ:IMMX
Intrinsic Alpha fair value
Locked
Current Price
$7.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.